A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-23

Study Completion Date

2023-12-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn about:

* how Zavegepant is changed and removed from the body after taken.
* safety of Zavegepant.
* the extent to which side effects can be tolerated after taking Zavegepant for the possible short-term treatment of migraine.

This study is seeking participants who:

* are healthy Chinese adults and includes participants who are between 18 to 55 years old.
* have body mass index (BMI) of 18 to 30 kg/m\^2.
* have a total body weight of:
* equal to or more than 50 kilograms (110 pounds) for males.
* equal to or more than 45 kilograms (99 pounds) for females.
* are non-smoker (no use of tobacco or nicotine products).

All participants in this study will receive Zavegepant by nose, once at the study clinic.

The experiences of the participants receiving the study medicine will be looked at. This will help see if the study medicine is safe.

Participants will take part in this study for around 9 weeks. During this time, participants will have 2 study visits at the study clinic and 1 contact over the phone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

NCT05989048

Migraine

COMPLETED PHASE3

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

NCT06995729

Acute Treatment of Migraine

RECRUITING PHASE1

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

NCT04804033

Migraine

TERMINATED PHASE2/PHASE3

Randomized Trial in Adult Participants With Acute Migraines

NCT04571060

Migraine

COMPLETED PHASE3

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

NCT06401642

Migraine

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zavegepant

Participants receiving Zavegepant for the treatment phase of the study

Group Type EXPERIMENTAL

Zavegepant

Intervention Type DRUG

Participants receiving single dose of Zavegepant 10 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zavegepant

Participants receiving single dose of Zavegepant 10 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Chinese adults and includes participants who are between 18 to 55 years old
* BMI of 18 to 30 kg/m\^2; and a total body weight ≥50 kg (110 lb) for males and ≥45 kg (99 lb) for females
* Non-smoker (no use of tobacco or nicotine products).

Exclusion Criteria

* Evidence or history of clinically significant disease.
* Use of medication other than topical products without significant systemic absorption.
* Previous participantion in a clinical research study or investigational study prior to the first dosing.
* Any clinically significant abnormal laboratory test results or positive test.
* Evidence of organ dysfunction or any clinically significant deviation from normal.
* Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic).
* Standard 12-lead ECG that demonstrates clinically relevant abnormalities.
* Abnormalities in clinical laboratory tests: AST or ALT level \> ULN; Total bilirubin level \> ULN; ANC or ALC level \> ULN.
* Positive urine drug screen, alcohol breath test, or urine cotinine test.
* Positive pregnancy test.
* Positive result for COVID-19.
* History of significant alcohol abuse or drug abuse.
* History of anaphylaxix reaction or a clinically important reaction to any drug.
* Donation of plasma within 30 days prior to dosing. Donation or loss of blood of approximately 400 mL or more within 60 days prior to dosing.
* Inability to be venipunctured and/or tolerate catheter venous access.
* Habitual use of snuff tobacco.
* History of sensitivity to heparin or heparin-induced thrombocytopenia.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes